

# 해외 바이오의약품 임상 현황 ('23년 11월 3주)

한국바이오의약품협회, 2023.11.21.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.11.13.~2023.11.19.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 17건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05643729</a>	Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)	Drug: Zofin Other: Placebo	Organicell Regenerative Medicine	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05643729&amp;rank=1</a>
<a href="#">NCT04129515</a>	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT04129515&amp;rank=1</a>
<a href="#">NCT06063850</a>	AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Genetic: AAV9-hSyn1-miGRIK2	uniQure France SAS UniQure Biopharma B.V.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06063850&amp;rank=1</a>
<a href="#">NCT06124118</a>	Tumor Treating Fields for Locally Advanced NSCLC	Radiation: carboplatin chemotherapy Device: NovoTTF-200T (TTFields) System Drug: Durvalumab	University of Utah	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06124118&amp;rank=1</a>
<a href="#">NCT06056895</a>	Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Biological: Retifanlimab Drug: Tupaerstobart Drug: Verzistobart	University of Washington Incyte Corporation	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06056895&amp;rank=1</a>
<a href="#">NCT05794659</a>	Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer	Biological: AST-201 Drug: Paclitaxel Drug: Carboplatin Drug: Placebo Drug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)	Aston Sci. Inc.	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05794659&amp;rank=1</a>
<a href="#">NCT05223816</a>	An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma	Drug: VG161 Drug: Nivolumab Injection [Opdivo]	Virogin Biotech Canada Ltd Virogin Biotech Ltd.	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05223816&amp;rank=1</a>
<a href="#">NCT04482933</a>	HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma	Drug: Biological G207	Pediatric Brain Tumor Consortium Treovir, LLC	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT04482933&amp;rank=1</a>
<a href="#">NCT06091254</a>	A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma	Drug: Odronextamab Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone/prednisolone Drug: Bendamustine	Regeneron Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06091254&amp;rank=1</a>
<a href="#">NCT06132126</a>	A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus	Drug: LY3938577 Drug: Placebo Drug: Insulin degludec	Eli Lilly and Company	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT06132126&amp;rank=1</a>

# 해외 바이오의약품 임상 현황 ('23년 11월 3주)

한국바이오의약품협회, 2023.11.21.

## ○ 미국 17건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05306353</a>	CD40L Antagonism in Rheumatoid Arthritis (RA)	Drug: Placebo for VIB4920 Drug: VIB4920 with TNFi Drug: VIB4920 without TNFi	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05306353</a>
<a href="#">NCT06024174</a>	A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors	Drug: BMS-986466 Drug: Adagrasib Drug: Cetuximab	Bristol-Myers Squibb	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06024174</a>
<a href="#">NCT06131437</a>	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	Drug: Cagrilintide Drug: Semaglutide Drug: Tirzepatide	Novo Nordisk A/S	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06131437</a>
<a href="#">NCT06112379</a>	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Pembrolizumab Drug: Doxorubicin Drug: Epirubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Carboplatin Drug: Capecitabine Drug: Olaparib	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06112379</a>
<a href="#">NCT06103864</a>	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Pembrolizumab	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06103864</a>
<a href="#">NCT06079372</a>	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06079372</a>
<a href="#">NCT05920356</a>	A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreak 202)	Drug: Sotorasib Drug: Pembrolizumab	Amgen	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05920356</a>

## ○ 영국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06103864</a>	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Pembrolizumab	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06103864</a>
<a href="#">NCT06112379</a>	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Pembrolizumab Drug: Doxorubicin Drug: Epirubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Carboplatin Drug: Capecitabine Drug: Olaparib	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06112379</a>
<a href="#">NCT06079372</a>	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06079372</a>

# 해외 바이오의약품 임상 현황 ('23년 11월 3주)

한국바이오의약품협회, 2023.11.21.

## ○ 프랑스 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06024174</a>	A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors	Drug: BMS-986466 Drug: Adagrasib Drug: Cetuximab	Bristol-Myers Squibb	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06024174">https://clinicaltrials.gov/ct2/show/study/NCT06024174</a>
<a href="#">NCT06112379</a>	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Pembrolizumab Drug: Doxorubicin Drug: Epirubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Carboplatin Drug: Capecitabine Drug: Olaparib	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06112379">https://clinicaltrials.gov/ct2/show/study/NCT06112379</a>
<a href="#">NCT06079372</a>	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06079372">https://clinicaltrials.gov/ct2/show/study/NCT06079372</a>

## ○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06112379</a>	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Pembrolizumab Drug: Doxorubicin Drug: Epirubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Carboplatin Drug: Capecitabine Drug: Olaparib	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06112379">https://clinicaltrials.gov/ct2/show/study/NCT06112379</a>
<a href="#">NCT06103864</a>	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Pembrolizumab	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06103864">https://clinicaltrials.gov/ct2/show/study/NCT06103864</a>
<a href="#">NCT06079372</a>	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06079372">https://clinicaltrials.gov/ct2/show/study/NCT06079372</a>

## ○ 중국 12건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06136351</a>	A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma	Drug: Zanubrutinib Drug: Rituximab Drug: Bendamustine	Ruijin Hospital	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06136351">https://clinicaltrials.gov/ct2/show/study/NCT06136351</a>
<a href="#">NCT06134960</a>	NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor	Biological: KD-496	Peking University KAEDI	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06134960">https://clinicaltrials.gov/ct2/show/study/NCT06134960</a>
<a href="#">NCT06132789</a>	A Clinical Trial of Rabies Vaccine(Human Diploid Cell) for Human Use,Freeze-dried in a Population Aged 10-60 Years	Biological: Rabies Vaccine(Human Diploid Cell) for Human Use,Freeze-dried	Ab&b Biotechnology Co., Ltd.JS Hubei Provincial Center for Disease Control and Prevention	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06132789">https://clinicaltrials.gov/ct2/show/study/NCT06132789</a>
<a href="#">NCT06125106</a>	Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab	Drug: Blinatumomab	Zhejiang University	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06125106">https://clinicaltrials.gov/ct2/show/study/NCT06125106</a>

# 해외 바이오의약품 임상 현황 ('23년 11월 3주)

한국바이오의약품협회, 2023.11.21.

## ○ 중국 12건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06124378</a>	Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer	Drug: Tislelizumab Drug: Oxaliplatin Drug: Capecitabine Procedure: Colectomy	First Affiliated Hospital of Guangxi Medical University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06124378</a>
<a href="#">NCT06091124</a>	Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma	Drug: Adebrelimab Drug: Etoposide Drug: Cisplatin Procedure: Radical Cystectomy	RenJi Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06091124</a>
<a href="#">NCT05970666</a>	Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma	Drug: TACE with adebreliumab and bevacizumab	The First Affiliated Hospital of Xiamen University Jiangsu HengRui Medicine Co., Ltd.	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05970666</a>
<a href="#">NCT05960955</a>	Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Drug: Cadonilimab Drug: AK117 Drug: Oxaliplatin Drug: Tegafur-gimeracil-oteracil potassium Drug: Docetaxel Drug: 5-Fluorouracil	Akeso	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05960955</a>
<a href="#">NCT05839470</a>	Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer	Drug: cadonilimab Drug: irinotecan Drug: Oxaliplatin Drug: leucovorin or levoleucovorin Drug: 5-FU	Fujian Cancer Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05839470</a>
<a href="#">NCT05990127</a>	A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer	Drug: AK104 Drug: Tislelizumab Drug: carboplatin Drug: Pemetrexed Drug: Paclitaxel	Akeso	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05990127</a>
<a href="#">NCT06103864</a>	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Pembrolizumab	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06103864</a>
<a href="#">NCT06112379</a>	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Pembrolizumab Drug: Doxorubicin Drug: Epirubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Carboplatin Drug: Capecitabine Drug: Olaparib	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06112379</a>

## ○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06103864</a>	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Drug: Dato-DXd Drug: Durvalumab Drug: Paclitaxel Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Pembrolizumab	AstraZeneca Daiichi Sankyo, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06103864</a>
<a href="#">NCT06079372</a>	Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa	Drug: ALXN1850 Drug: asfotase alfa	Alexion Pharmaceuticals, Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06079372</a>
<a href="#">NCT05920356</a>	A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreak 202)	Drug: Sotorasib Drug: Pembrolizumab	Amgen	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05920356</a>